Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

by · The Markets Daily

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $6.2333.

Several research analysts have recently commented on IRWD shares. Weiss Ratings lowered Ironwood Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, September 4th. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th.

Read Our Latest Stock Analysis on IRWD

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. The trade was a 28.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in Ironwood Pharmaceuticals by 529.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock worth $7,307,000 after buying an additional 1,751,219 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in Ironwood Pharmaceuticals in the first quarter valued at about $3,982,000. Inspire Investing LLC purchased a new stake in Ironwood Pharmaceuticals in the first quarter valued at about $1,790,000. Bank of New York Mellon Corp acquired a new stake in Ironwood Pharmaceuticals in the second quarter worth about $2,142,000. Finally, Globeflex Capital L P acquired a new stake in Ironwood Pharmaceuticals in the second quarter worth about $1,094,000.

Ironwood Pharmaceuticals Stock Up 1.4%

Shares of IRWD stock opened at $4.23 on Friday. The firm has a market cap of $698.97 million, a price-to-earnings ratio of 5.49 and a beta of 0.20. The company’s 50 day moving average is $4.13 and its 200 day moving average is $3.89. Ironwood Pharmaceuticals has a 52-week low of $1.26 and a 52-week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $113.04 million for the quarter, compared to analysts’ expectations of $114.84 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. Analysts anticipate that Ironwood Pharmaceuticals will post 1.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

(Get Free Report)

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain.

Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S.

Featured Stories